XML 47 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) - AstraZeneca Agreements [Member] - U.S./RoW and China [Member]
$ in Millions
Mar. 31, 2025
USD ($)
License [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration $ 344.5
Product [Member]  
Disaggregation of Revenue [Line Items]  
Cumulative Revenue 391.7
Co-development, information sharing & committee services [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration 625.5
China performance obligation [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration $ 522.5